Voyager Therapeutics(US:VYGR)2025-08-06 20:00Financial Performance - Collaboration revenue for Q2 2025 was $5.2 million, a decrease of 82.4% from $29.6 million in Q2 2024[4] - Net loss for Q2 2025 was $33.4 million, compared to $10.1 million in Q2 2024, reflecting decreased collaboration revenue[4] - General and administrative expenses increased slightly to $10.5 million in Q2 2025 from $10.2 million in Q2 2024[4] - Net collaboration revenue for the first half of 2025 was $7.7 million, down from $43.9 million in the same period of 2024[19] Research and Development - R&D expenses decreased to $31.3 million in Q2 2025 from $34.5 million in Q2 2024, primarily due to non-recurring items[4] - GAAP total research and development expenses for Q2 2025 were $31.3 million, compared to $34.5 million in Q2 2024[19] - Net research and development expenses for the first half of 2025 were $58.8 million, an increase from $56.4 million in the first half of 2024[19] - The company incurred $2.4 million in reimbursable research and development services in Q2 2025, up from $2.0 million in Q2 2024[19] - Total reimbursable research and development services for the first half of 2025 amounted to $4.0 million, compared to $5.1 million in the first half of 2024[19] Cash Position - Cash runway extended into 2028, enabling multiple meaningful clinical data read-outs[1] - Cash, cash equivalents, and marketable securities as of June 30, 2025, were $262 million[4] Pipeline Developments - The company has 11 partnered programs with potential for $2.6 billion in development-stage milestone payments[1] - VY7523 (anti-tau antibody) initial tau PET data expected in H2 2026[2] - VY1706 (tau silencing gene therapy) anticipated to enter clinical trials in 2026[2] - New APOE program added to the pipeline for Alzheimer's disease in June 2025[5]